Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 3/2014

ROLE OF ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS IN HYPERTENSION AND CARDIOVASCULAR PROTECTION MANAGEMENT

MONICA ŢÂNŢU1, EDUARD BELU2, ELENA BOBESCU3, SEBASTIAN-MIHAI ARMEAN4, PETRU ARMEAN5, MARIA MAGDALENA CONSTANTIN5*, CARMEN DANIELA DOMNARIU6

1.University of Piteşti, Faculty of Sciences, Department of Medical Care Assistance and Kinesiotherapy, str. Târgu din Vale, nr.1, cod 110040, Piteşti, Argeş, România
2 .County Emergency Hospital Brasov, Cardiology Department
3 .Transilvania University of Brasov, Faculty of Medicine, Department of Medical and Surgical Specialties
4 .Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Department of Pharmacology, Toxicology and Clinical Pharmacology, Cluj-Napoca, Romania
5 .Carol Davila University of Medicine and Pharmacy Bucharest
6 .Lucian Blaga University of Sibiu, Faculty of Medicine, Department IV

Download Full Article PDF

Angiotensin converting enzyme (ACE) inhibitors plays an important role in hypertension and cardiovascular protection management, both alone and in various combinations with other pharmacological agents from different classes. This position is supported by the significant hemodynamic, cardiac effect, renal effect, antithrombotic and neurohormonal effects of these pharmacological agents, effects demonstrated in clinical trials with a significant number of patients analysed. ACE inhibitors have proven their efficacy and safety in blood pressure control, as well as a substantial influence in reducing cardiovascular risk, at the same time having target organ protection. The main result of ACE inhibitors therapy is to improve quality of life and reduce cardiovascular morbidity and mortality.